Table 1.
Antiviral activities of medicinal fungi and their mechanism of action in human viruses.
| Virus | Chemical Class | Antiviral Agent | Source | Action Mechanism | Reference | |
|---|---|---|---|---|---|---|
| SARS-CoV-2 | Polysaccharide | L-fucose–containing polysaccharides | Ganoderma lucidum | Vitro | [12] | |
| Triterpenes, protein | Ganoderma lucidum, Grifola frondosa et al. | Inhibition ACE activity | [13] | |||
| Steroid | Antcins | Antrodia cinnamomea | ACE2 inhibitory effect | [14] | ||
| Polysaccharide | 20% α-glucans | Lentinus edodes | Regulating the immune system | [15] | ||
| Polysaccharide | Carbosynth-lentinan (50%β-glucan 12%α-glucan) | Lentinus edodes | Reduce the level of inflammation in the lung |
[16] | ||
| Polysaccharide | In-house Lentinan (72%β-glucan) | Lentinus edodes | Reduce the level of inflammation in the lung | [16] | ||
| Adenosine | Cordycepin(C10H13N5O3) | Cordyceps sinensis | Spike protein inhibitor | [17] | ||
| IV | Crude extract | ME, MFs (MF1, MF2 and MF3) | Grifola frondosa | Vitro induce the production of cytokines such as TNF-α, which inhibit the growth of virus in vitro. | [18] | |
| Pyranone | Phelligridins E, G | Phellinus igniarius | Vitro neuraminidase inhibitory activity | [19] | ||
| Crude extract | Aqueous extract PIW | Phellinus igniarius | Vitro interfering with the early replication process of the virus | [20] | ||
| Crude extract | Lentinus edodes mycelium extract LEM | Lentinus edodes | Vitro Inhibit virus entry into host cells activate the immune response through the type I IFN pathway | [21] | ||
| Terpenoids | Cryptoporic acid E | Cryptoporus volvatus | Vitro | [22] | ||
| Crude extract | Water extract | Cryptoporus volvatus | Vitro | [23] | ||
| Polysaccharide | APS (D-galactose, L-arabinose, D-xylose, L-rhamnose, and D-galacturonic acid) |
Cordyceps militaris | Vitro | [24] | ||
| Crude extract | Cordyceps militaris | Vivo increased IL-12 expression and greater number of NK cells | [25] | |||
| Crude extract | Auuriporia aurea, Flammulina velutipes, Fomes fomentarius, Ganoderma lucidum, Lentinus edodes, Lyophyllum shimeji, Pleurotus eryngii, Pleurotus ostreatus, Schizophyllum commune, and Trametes versicolor | Vitro | [26] | |||
| Fatty acid | (2Z,4E)-deca-2,4-dienoic acid (DDEA) | Cordyceps sinensis | Reduce the level of inflammation caused by infection with H1N1 | [27] | ||
| Polysaccharide | PCP-II (fucose, mannose, glucose and galactose in molar ration of 1.00:1.63:0.16:6.29) | Poria cocos | Vaccine adjuvant | [28] | ||
| Polysaccharide | Mixed polysaccharides (MPs) | shiitake mushroom, poriacocos, ginger, tangerine peel | Enhanced the level of cellular immunity and humoral immunity | [29] | ||
| EV71 | Polysaccharide | Neutral polysaccharide having a β-1,6-linked Glcp backbone with 1,3-α-glucan units | Grifola frondosa | Vitro Inhibition of VP1 protein expression and genomic RNA synthesis | [30] | |
| Polysaccharide | 95%polysaccharides (glucose 79% and mannose 21%) and 5% proteins | Ganoderma lucidum | Vaccine adjuvant | [31] | ||
| Triterpenoid | Lanosta-7,9(11),24-trien-3one,15;26-dihydroxy (GLTA) and Ganoderic acid Y (GLTB) | Ganoderma lucidum | Vitro inhibits the replication of the viral RNA replication through blocking EV71 uncoating | [32] | ||
| HIV | Adenosine | Cordycepin(C10H13N5O3) | Cordyceps sinensis | Vitro inhibitory activity on HIV-1 reverse transcriptase IC50 8.2 × 10−3 μM | [33] | |
| Water extract | Cordyceps sinensis | Vitro inhibitory activity on HIV-1 reverse transcriptase | [34] | |||
| Adenosine | L3a(C10H13N5O4), L3b(C20H20O7), L3c(C12H17N5O5) | Cordyceps militaris | Vitro inhibitory activity on HIV-1 reverse transcriptase | [35] | ||
| Lectin | N-terminal amino acid sequence (NSTDISLNHG) Molecular mass 30 kDa |
Cordyceps militaris | Vitro inhibitory activity on HIV-1 reverse transcriptase IC50 10 μM | [36] | ||
| Lectin | N-terminal amino acid sequence (QYSQMAQVME) Molecular mass 32.4 kDa |
Pleurotus ostreatus | Vitro inhibitory activity on HIV-1 reverse transcriptase IC50 0.93 μM | [37] | ||
| Protein | N-terminal amino acid sequence (AEGTLLGSRA TCESGNSMY) Molecular mass 9567 Da, |
Hypsizigus marmoreus | Vitro inhibitory activity on HIV-1 reverse transcriptase IC50 30 nM |
[38] | ||
| Protein | N-terminal amino acid sequence(XHPDLFXX) molecular mass 13.8 kDa |
Flammulina velutipes | Vitro inhibitory activity on HIV-1 reverse transcriptase | [39] | ||
| Hemolysin | N-terminal amino acid sequence (ATNYNKCPGA) Molecular mass 29 kDa |
Schizophyllum commune | Vitro inhibitory activity on HIV-1 reverse transcriptase IC50 1.8 mM | [40] | ||
| Ribonuclease | N-terminal amino acid sequence (TPYLDYLAAL QADGPVVPFIRNWEGALSIS) Molecular mass 20 kDa | Schizophyllum commune | Vitro inhibitory activity on HIV-1 reverse transcriptase IC50 65 mM |
[41] | ||
| Crude extract | NGCs and AGCs | Ganoderma lucidum | Vitro inhibitory effects on the attachment of HIV-1 glycoprotein 120 to cluster of differentiation 4 | [42] | ||
| Triterpenoid | Ganoderic acid B | Ganoderma lucidum | Vitro inhibitory activity on HIV-1 reverse transcriptase | [43] | ||
| Triterpenoid | Ganoderic acid β, lucidumol B, ganodermanondiol, ganodermanontriol, ganolucidic acid A | Ganoderma lucidum | Vitro inhibitory activity on HIV-1 reverse transcriptase IC50 20, 50, 90, 70, 70 μM |
[44] | ||
| Triterpenoid | Ganoderiol F and ganodermanontriol | Ganoderma lucidum | Vitro anti-hiv-1 activity with an inhibition concentration of 7.8 μg/mL | [45] | ||
| Triterpenoid | Ganoderic acid B, ganoderiol B, ganoderic acid C1, 3b-5a-dihydroxy-6b-methoxyergosta-7,22-diene, ganoderic acid a, ganoderic acid H and ganoderiol A | Ganoderma lucidum | Vitro inhibitory activity on HIV-1 reverse transcriptase IC50 0.17–0.23 mM |
[45] | ||
| Polysaccharide | PSP (28% polysaccharide-to-peptide ratio and a composition of 60.23 mg/g beta-1,3/1,6-glucan) | Coriolus versicolor | Vitro inhibitory activity on HIV-1 reverse transcriptase IC50 6.25 μg/mL inhibition of the interaction between HIV-l gp120 and immobilized CD4 receptor |
[46,47] | ||
| Laccase | N-terminal amino acid sequence (AGTSHFADL) molecular mass 67 kDa |
Lentinus edodes | Vitro inhibitory activity on HIV-1 reverse transcriptase IC50 7.5 µM |
[48] | ||
| Protein | N-terminal amino acid sequence (CQRAFNNPRDDAIRW) molecular mass 27.5 kDa | Lentinus edodes | Vitro inhibitory activity on HIV-1 reverse transcriptase IC50 1.5 µM |
[49] | ||
| Lignin | The elemental analysis; C, 44.6%; H, 4.68%; N, 1.74% | Lentinus edodes | Vitro | [50] | ||
| Water extract | E-P-LEM and LEM | Lentinus edodes | Vitro | [51] | ||
| HPV | Crude extract | Fruit body powders | Trametes versicolor, Ganoderma lucidum | Vivo | [52] | |
| Crude extract | Non-hormonal gel | Trametes versicolor | Vivo | [53] | ||
| DENV | Conidia | Conidia | Beauveria bassiana | Vivo activation of the mosquito’s anti-dengue Toll and JAK-STAT pathways | [54] | |
| Adenosine | Cordycepin(C10H13N5O3) | Cordyceps sinensis | Vitro inhibition of viral RNA replication | [55] | ||
| Crude extract | Hot aqueous extracts, and aqueous soluble extracts | rhinocerotis, Pleurotus giganteus, Hericium erinaceus, Schizophyllum commune | Vitro | [56,57] | ||
| Aqueous extract | Hesperidin | Ganoderma lucidum | Vitro anti-DENV NS2B-NS3 protease activity | [58] | ||
| Triterpene | Ganodermanontriol | Ganoderma lucidum | Vitro | [59] | ||
| HV | HBV | Crude extract | Crude extract | Cordyceps sinensis | Reduce apoptosis of renal tubular epithelial cells | [60] |
| Crude extract | GF-D extract | Grifola frondosa | Vitro directly interferes with HBV replication at the level of DNA polymerase | [61] | ||
| Polysaccharide | β-glucan with a (1-3)-β-glucose backbone and (1-6)-β-glucose side chains | Polyporus umbellatus | Treat hepatitis caused by HBV | [62] | ||
| Polysaccharide | Glucan | Schizophyllum commune | Modulate both cellular and humoral immune responses | [63] | ||
| Crude extract | Co-fermented broth | Ganoderma lucidum and Radix Sophorae flavescentis | Vitro | [64] | ||
| Triterpene | Ganoderic | Ganoderma lucidum | Vitro | [65] | ||
| Polysaccharide | LEP-1 (glucose72.15%, galactose12.12%, mannose10.02%) LEP-2(glucose79.49%, galactose7.12%, mannose6.92%) |
Lentinus edodes | Vitro | [66] | ||
| HCV | Crude extract | MSCE and LM-lignin | Lentinula edodes | Inhibit the entry of HCVpv into cells | [67] | |
| Adenosine | Cordycepin(C10H13N5O3) | Cordyceps militaris | Inhibit HCV RNA replication in vitro inhibit NS5B polymerase activity | [68] | ||
| HV | HSV | Protein | N-terminal amino acid sequence (NH2-REQDNAPCGLN-COOH) molecular mass 29.5 kDa |
Grifola frondosa | Vitro and vivo | [69] |
| Crude extract |
JLS-SO01 | Lentinus edodes | Vitro blocks HSV-I replication at the later stage of the virus replication cycle | [70] | ||
| Polysaccharide | APBP polysacchride (approximately 40.6%) and protein (approximately 7.80%) carbohydrates molar ratio (C:H:O = 1:2:1) | Ganoderma lucidum | Vitro | [71,72,73] | ||
| Crude extract | Water-soluble extracts GLhw and GLlw and eight kinds of methanol-soluble extracts GLMe-1-8 | Ganoderma lucidum | Vitro | [74] | ||
| Crude extract | Herbal mixture WTTCGE | Ganoderma lucidum | Vivo | [75] | ||
| EBV | Adenosine | Cordycepin(C10H13N5O3) | Cordyceps sinensis | Vitro Affect the synthesis of viral proteins by acting on the genes of EBV | [76] | |
| Terpenoid | lucidenic acid P, methyl lucidenates P, methyl lucidenates Q | Ganoderma lucidum | Inhibitory effects on Epstein-Barr virus early antigen induction | [77] | ||
| Terpenoid | Ganoderic acid A, ganoderic acid B, ganoderol B, ganodermanontriol, ganodermanondiol |
Ganoderma lucidum | Vitro | [78] | ||
| RSV | Protein | 114 amino acid residues molecular mass 13 kDa |
Flammulina velutipes | In vivo reduce the viral titers of RSV reducing NF-jB translocation | [79] | |
| PV | Crude extract polysaccharide |
LeP(β-D-glucan) aqueous (AqE) and ethanol (EtOHE) extracts |
Lentinus edodes | Vitro | [80] | |
| RV | Polysaccharide | Fucose, mannose, glucose and galactose at a molar ratio 1.00:1.63:0.16:6.29. | Poria cocos | Adjuvant for rabies vaccine | [81] | |
| MARV | Polysaccharide | PCP-II (fucose, mannose, glucose and galactose in molar ration of 1.00:1.63:0.16:6.29) | Poria cocos | Vaccine adjuvant | [82,83] | |